摘要
目的探讨预防性应用聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)在防治乳腺癌化疗后中性粒细胞减少中的价值及对患者生命质量的影响。方法选择2018年1月—2019年6月陆军军医大学大坪医院诊治的乳腺癌患者160例为研究对象。依据随机数字法将其分为试验组(80例)和对照组(80例)。所有患者接受6个周期TEC化疗方案,在此基础上试验组预防性使用PEG-rhG-CS,对照组预防性使用重组人粒细胞刺激因子(rhG-CSF),比较两组防治效果及安全性。生命质量测定量表(FACT-B)比较两组生命质量。结果两组发热性中性粒细胞减少症发生率比较,差异无统计学意义(P>0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。化疗后,试验组生理状况、社会/家庭情况、情感状况、功能状况、附加关注状况和总分均高于对照组,差异均有统计学意义(均P<0.05)。结论预防性应用PEG-rhG-CSF可以有效防治乳腺癌化疗中中性粒细胞减少和FN的发生,并且更有利于维持更高的生命质量。
Objective To investigate the value of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF)in preventing chemotherapy-induced neutropenia in breast cancer and the influence on quality of life.Methods A total of 160 patients with breast cancer treated in Daping Hospital,Army Medical University from January 2018 and June 2019 were selected as study odjects.According to the random number method,they were divided into the experimental group(80 cases)and the control group(80 cases).All patients received a six cycle TEC chemotherapy programme,on this basis,the experimental group was prophylactic use of PEG-rhG-CS,while the control group was prophylactic use of recombinant human granulocyte colony-stimulating factor(rhG-CSF).The efficacy and safety of the two groups were compared.The quality of life scale(FACT-B)was compared between the two groups.Results The incidence of febrile neutropenia between the two groups was not statistically significant(P>0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).After chemotherapy,physiological status,social/family status,emotional status,functional status,additional attention status and total score of the experimental group were all higher than those of the control group,with statistically significant differences(all P<0.05).Conclusion Prophylactic use of PEG-rhG-CSF can effectively prevent the occurrence of neutropenia and FN in breast cancer chemotherapy,and is more conducive to maintaining a higher quality of life.
作者
黄苗
田武国
郝帅
HUANG Miao;TIAN Wuguo;HAO Shuai(Nursing School,Chongqing Medical University,Chongqing 400016,China;Department of Breast and Thyroid Surgery,Daping Hospital,Army Medical University,Chongqing 400042,China)
出处
《中国医药导报》
CAS
2020年第32期96-99,共4页
China Medical Herald
基金
重庆市科卫联合医学科研项目(2019QNXM027)。
关键词
乳腺癌
聚乙二醇化重组人粒细胞刺激因子
辅助化疗
中性粒细胞减少
生命质量
Breast cancer
Pegylated recombinant human granulocyte colony-stimulating factor
Adjuvant chemo-therapy
Neutropenia
Quality of life
